Donaldson Capital Management LLC Has $1.10 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Donaldson Capital Management LLC cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,915 shares of the biopharmaceutical company’s stock after selling 105 shares during the period. Donaldson Capital Management LLC’s holdings in Gilead Sciences were worth $1,101,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. HHM Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares in the last quarter. YANKCOM Partnership bought a new stake in Gilead Sciences during the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences in the fourth quarter valued at $29,000. Crews Bank & Trust acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $31,000. Finally, Stephens Consulting LLC raised its holdings in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 260 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

GILD stock opened at $114.43 on Wednesday. The firm has a 50 day moving average of $100.56 and a 200-day moving average of $92.18. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The firm has a market capitalization of $142.50 billion, a P/E ratio of 309.27, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.76%. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total value of $260,225.00. Following the completion of the sale, the chief financial officer now owns 169,061 shares of the company’s stock, valued at $17,597,559.49. This trade represents a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 293,356 shares of company stock valued at $29,166,240 over the last ninety days. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Morgan Stanley increased their price target on Gilead Sciences from $123.00 to $130.00 and gave the stock an “overweight” rating in a report on Tuesday. Cantor Fitzgerald reissued a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Wolfe Research started coverage on shares of Gilead Sciences in a report on Friday, November 15th. They set an “outperform” rating and a $110.00 price objective on the stock. The Goldman Sachs Group raised their target price on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Finally, Citigroup assumed coverage on Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 price target on the stock. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $104.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.